US President Joe Biden announced that they have purchased 10 million units of the oral coronavirus drug developed by Pfizer, and are awaiting approval from the Food and Drug Administration.
US President Joe Biden stressed that the antiviral drug developed by Pfizer at the beginning of this month significantly reduces the risk of hospitalization and death of people infected with the Coronavirus.
Biden confirmed that the drug in question is currently awaiting approval by the Food and Drug Administration (FDA), “However, urgent steps have been taken to ensure an adequate supply is provided to the American people.
Today we have purchased 10 million units of Pfizer Antivirals of these drugs before the end of this year, and I am proud to announce that they will be distributed during 2022.”
Biden stressed that he “made the necessary preparations so that the drugs would be available and free to all.”
And that the drug in question will speed them up in the fight against the epidemic, but vaccines are still their most powerful weapon.
Pfizer announced that it had signed a $5.29 billion deal with the US government to deliver 10 million drugs.
In the statement made by the company, it was stated that if approved by the Food and Drug Administration, delivery of the drug would begin this year.
On November 16, the US drug company Pfizer filed an application with the Food and Drug Administration (FDA).
To obtain the oral drug it developed against the coronavirus for use in moderate and high-risk patients.
If the drug in question is approved by the Food and Drug Administration, it will be sold under the name “Paxlovid” within a few weeks and used to treat people who weren’t vaccinated in the first place.
And Pfizer previously announced that its drugs reduced death rates by 89 percent in patients at medium- and high-risk.
Merck, another US pharmaceutical company, applied to the US Food and Drug Administration on October 11 for emergency approval for the drug it developed against the coronavirus.
England was the first country to approve the use of Merck’s drug molnopiravir.
Merck reported that Molnopiravir reduces the risk of hospitalization and death by 50 percent in people who have recently contracted the virus.